|
AU757658B2
(en)
*
|
1998-03-09 |
2003-02-27 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
|
CN101094867B
(zh)
|
2004-10-19 |
2011-08-24 |
隆萨股份公司 |
用于固相肽合成的方法
|
|
MX2007013431A
(es)
|
2005-05-04 |
2008-01-18 |
Zealand Pharma As |
Analogos del peptido 2 semejante al glucagon.
|
|
GB0514071D0
(en)
|
2005-07-07 |
2005-08-17 |
Zealand Pharma As |
N- or C- terminally modified small peptides
|
|
WO2007060860A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Nihon University |
ピロールイミダゾールポリアミドの固相自動合成
|
|
DK1966130T3
(da)
|
2005-12-23 |
2014-02-10 |
Zealand Pharma As |
Modificerede lysin-mimetiske forbindelser
|
|
WO2007097561A1
(en)
*
|
2006-02-20 |
2007-08-30 |
Ewha University - Industry Collaboration Foundation |
Peptide having cell membrane penetrating activity
|
|
DK2000474T3
(en)
*
|
2006-03-29 |
2018-01-22 |
Glytech Inc |
PROCEDURE FOR PRODUCING A PEPTID THIOESTER COMPOUND
|
|
AU2007319066B2
(en)
|
2006-11-08 |
2013-09-19 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
|
JP5385266B2
(ja)
|
2007-06-15 |
2014-01-08 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
PL2370462T3
(pl)
|
2008-12-15 |
2015-01-30 |
Zealand Pharma As |
Analogi glukagonu
|
|
MX2011006314A
(es)
|
2008-12-15 |
2011-09-22 |
Zealand Pharma As |
Analogos de glucagon.
|
|
EA020537B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
AU2008365557A1
(en)
|
2008-12-15 |
2011-07-21 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AP3329A
(en)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
|
CA2797133C
(en)
|
2010-04-27 |
2019-08-06 |
Zealand Pharma A/S |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
KR20130086343A
(ko)
|
2010-06-24 |
2013-08-01 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
|
SG192038A1
(en)
|
2011-01-20 |
2013-08-30 |
Zealand Pharma As |
Combination of acylated glucagon analogues with insulin analogues
|
|
TW201326194A
(zh)
|
2011-11-03 |
2013-07-01 |
Zealand Pharma As |
Glp-1胃泌素受體促效劑肽結合物
|
|
KR20140114845A
(ko)
|
2011-12-23 |
2014-09-29 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
|
WO2013113916A2
(en)
|
2012-02-03 |
2013-08-08 |
Zealand Pharma A/S |
Ghrelin analogues
|
|
NZ702333A
(en)
|
2012-05-03 |
2017-06-30 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
|
TR201802689T4
(tr)
|
2012-05-03 |
2018-03-21 |
Zealand Pharma As |
Glukagon benzeri peptit-2 (glp-2) analogları.
|
|
MX356957B
(es)
|
2012-07-23 |
2018-06-20 |
Zealand Pharma As |
Analogos del glucagon.
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
US10450354B2
(en)
|
2013-03-12 |
2019-10-22 |
Molecular Templates, Inc. |
CD20-binding immunotoxins for inducing cellular internalization and methods using same
|
|
US9695214B2
(en)
|
2013-03-15 |
2017-07-04 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
US9169287B2
(en)
|
2013-03-15 |
2015-10-27 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
HUE034308T2
(en)
|
2013-03-21 |
2018-02-28 |
Sanofi Aventis Deutschland |
Preparation of hydantoin-containing peptide products
|
|
CN105102427B
(zh)
|
2013-03-21 |
2018-09-07 |
赛诺菲-安万特德国有限公司 |
含有环状酰亚胺的肽产物的合成
|
|
LT3057984T
(lt)
|
2013-10-17 |
2018-12-27 |
Zealand Pharma A/S |
Acilinti gliukagono analogai
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
KR102310392B1
(ko)
|
2013-11-06 |
2021-10-13 |
질랜드 파마 에이/에스 |
글루카곤-glp-1-gip 삼원 효능제 화합물
|
|
AU2014345569B2
(en)
|
2013-11-06 |
2020-08-13 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
WO2015100246A1
(en)
|
2013-12-24 |
2015-07-02 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
IL285403B2
(en)
|
2014-01-27 |
2023-10-01 |
Molecular Templates Inc |
Polypeptides that remove an epitope for MHC group I
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素aサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
SI3604333T1
(sl)
|
2014-03-11 |
2021-08-31 |
Molecular Templates, Inc. |
Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
|
|
EP3137488B1
(de)
|
2014-06-11 |
2019-01-02 |
Molecular Templates, Inc. |
Proteasespaltungsbeständige shigatoxin-a-untereinheiteffektorpolypeptide und zellgerichtete moleküle damit
|
|
EP3160995A2
(de)
|
2014-06-26 |
2017-05-03 |
Ossianix Inc. |
Halbsynthetische ammenhai-vnar-bibliotheken zur herstellung und verwendung von verbindungen mit selektiver bindung
|
|
RU2716985C2
(ru)
|
2014-10-29 |
2020-03-17 |
Зилэнд Фарма А/С |
Соединения-агонисты gip и способы
|
|
WO2016077840A2
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
|
|
KR20170110601A
(ko)
|
2015-02-05 |
2017-10-11 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
|
|
EA035791B1
(ru)
|
2015-03-18 |
2020-08-11 |
Зилэнд Фарма А/С |
Аналоги амилина
|
|
GB201506380D0
(en)
|
2015-04-15 |
2015-05-27 |
Serodus Asa |
Materials and methods for treatment of pulmonary hypertension
|
|
JP6989385B2
(ja)
|
2015-04-16 |
2022-01-05 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
|
HUE051246T2
(hu)
|
2015-05-30 |
2021-03-01 |
Molecular Templates Inc |
Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
|
|
MX2018001208A
(es)
|
2015-07-26 |
2018-03-26 |
Molecular Templates Inc |
Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
|
|
US10683325B2
(en)
|
2015-09-17 |
2020-06-16 |
Massachusetts Institute Of Technology |
Methods and systems for solid phase peptide synthesis
|
|
CA3033082A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
AR109514A1
(es)
|
2016-09-09 |
2018-12-19 |
Zealand Pharma As |
Análogos de amilina
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
SG10201911851VA
(en)
|
2016-12-09 |
2020-02-27 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
MX2019006600A
(es)
|
2016-12-09 |
2019-08-01 |
Zealand Pharma As |
Agonistas duales de glp-1/glp-2.
|
|
JP7082424B2
(ja)
|
2017-01-25 |
2022-06-08 |
モレキュラー テンプレーツ,インク. |
脱免疫化された志賀毒素aサブユニットエフェクター及びcd8+t細胞エピトープを含む細胞標的化分子
|
|
ES2894629T3
(es)
|
2017-06-16 |
2022-02-15 |
Zealand Pharma As |
Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
|
|
EP3704149A1
(de)
|
2017-11-02 |
2020-09-09 |
Ossianix, Inc. |
Verbesserte tfr-selektive bindungspeptide mit der fähigkeit zum passieren der blut-hirn-schranke
|
|
US11965039B2
(en)
|
2018-02-27 |
2024-04-23 |
Zp Spv 3 K/S |
Compstatin analogues and their medical uses
|
|
KR20200143634A
(ko)
|
2018-04-17 |
2020-12-24 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
|
|
US12258414B2
(en)
|
2018-06-22 |
2025-03-25 |
Ossianix, Inc. |
Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
|
|
CN120795059A
(zh)
|
2018-08-27 |
2025-10-17 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US12351642B2
(en)
|
2018-09-14 |
2025-07-08 |
Ossianix, Inc. |
TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
AU2020211407A1
(en)
|
2019-01-23 |
2021-08-12 |
Millennium Pharmaceuticals, Inc. |
Anti-CD38 antibodies
|
|
JP7418756B2
(ja)
|
2019-01-23 |
2024-01-22 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
脱免疫化志賀毒素aサブユニットエフェクターを含むcd38結合性タンパク質
|
|
SG11202111312UA
(en)
|
2019-06-14 |
2021-12-30 |
Zealand Pharma As |
Pharmaceutical parenteral composition of dual glp1/2 agonist
|
|
CN114630836A
(zh)
|
2019-08-27 |
2022-06-14 |
西兰制药第三特殊目的公司 |
补体抑制素类似物及其医学用途
|
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
CA3155089A1
(en)
|
2019-09-20 |
2021-03-25 |
Zealand Pharma A/S |
Kv1.3 blockers
|
|
WO2021102445A1
(en)
|
2019-11-24 |
2021-05-27 |
Molecular Templates, Inc. |
Uses of cd20-binding molecules and additional therapeutic agents
|
|
EP4126003A1
(de)
|
2020-03-30 |
2023-02-08 |
Zealand Pharma A/S |
Duale glp-1-/glp-2-agonisten
|
|
WO2021198195A1
(en)
|
2020-03-30 |
2021-10-07 |
Zealand Pharma A/S |
Agonist combination
|
|
US20230287051A1
(en)
|
2020-07-16 |
2023-09-14 |
Zp Spv 3 K/S |
Inhibitors of complement factor c3 and their medical uses
|
|
WO2022103769A1
(en)
|
2020-11-11 |
2022-05-19 |
Ossianix, Inc. |
High affinity human and monkey specific tfr-1 vnars
|
|
WO2022129311A1
(en)
|
2020-12-16 |
2022-06-23 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
AU2021401137B2
(en)
|
2020-12-16 |
2024-09-05 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
KR20230121822A
(ko)
|
2020-12-16 |
2023-08-21 |
질랜드 파마 에이/에스 |
Glp-1/glp-2 이중 효능제의 약학적 조성물
|
|
EP4294424B1
(de)
|
2021-02-18 |
2026-02-11 |
Zealand Pharma A/S |
Glp-1/glp-2-dualagonist zur behandlung des kurzdarmsyndroms
|
|
WO2022197945A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
BR112023019022A2
(pt)
|
2021-03-23 |
2023-10-17 |
Zealand Pharma As |
Bloqueadores de kv1.3
|
|
WO2022260877A1
(en)
|
2021-06-07 |
2022-12-15 |
Ossianix, Inc. |
Shark vnars for treating covid-19
|
|
KR20240022551A
(ko)
|
2021-06-18 |
2024-02-20 |
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 |
글루카곤 유사체 및 이의 의학적 용도
|
|
US20250122298A1
(en)
|
2021-08-17 |
2025-04-17 |
Ossianix, Inc. |
Deimmunized vnar domains and scaffolds
|
|
AU2022339044A1
(en)
|
2021-09-03 |
2024-03-14 |
Zealand Pharma A/S |
Dosage regime
|
|
CA3240982A1
(en)
|
2021-12-01 |
2023-06-08 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
MX2024005969A
(es)
|
2022-05-30 |
2024-06-11 |
Zealand Pharma As |
Formulaciones liquidas de analogos de amilina.
|
|
EP4593864A1
(de)
|
2022-09-28 |
2025-08-06 |
Zealand Pharma A/S |
Verfahren zur behandlung von adipositas
|
|
EP4604984A1
(de)
|
2022-10-18 |
2025-08-27 |
Zealand Pharma A/S |
Inhibitoren
|
|
WO2024168411A1
(pt)
*
|
2023-02-15 |
2024-08-22 |
Proteimax Bio Technology Israel Ltd |
Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
|
|
EP4471048A1
(de)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptidinhibitoren des interleukin-23-rezeptors
|
|
EP4471049A1
(de)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptidinhibitoren des interleukin-23-rezeptors
|
|
WO2025056677A1
(en)
|
2023-09-15 |
2025-03-20 |
Zealand Pharma A/S |
Dasiglucagon for use in the treatment of congenital hyperinsulinism
|
|
TW202528338A
(zh)
|
2023-12-04 |
2025-07-16 |
丹麥商西蘭製藥公司 |
方法
|
|
WO2025120001A1
(en)
|
2023-12-04 |
2025-06-12 |
Zealand Pharma A/S |
Amylin analogues for reducing consumption of high-fat food
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
US20250382332A1
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Novel alpha-factor based peptides with antifungal activity
|
|
US20250381242A1
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Antimicrobial peptides against citrus greening
|
|
WO2025262301A1
(en)
|
2024-06-20 |
2025-12-26 |
Zealand Pharma A/S |
Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake
|
|
WO2026003546A1
(en)
|
2024-06-27 |
2026-01-02 |
Vrg Miniprotein Zrt |
Potassium ion kv1.3 channel inhibitors
|
|
TW202607011A
(zh)
|
2024-07-12 |
2026-02-16 |
丹麥商西蘭製藥公司 |
介白素-23受體之胜肽抑制劑
|
|
WO2026052859A1
(en)
|
2024-09-09 |
2026-03-12 |
Zealand Pharma A/S |
Treatment with dapiglutide
|
|
WO2026052861A1
(en)
|
2024-09-09 |
2026-03-12 |
Zealand Pharma A/S |
Treatment with dapiglutide
|